Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.53bn
- Net income in CHF909.00m
- Incorporated2002
- Employees19.77k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Mergers & acquisitions
| Acquired company | LONN:SWX since announced | Transaction value |
|---|---|---|
| Redberry Sas | -10.13% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abivax SA | 0.00 | -178.01m | 7.65bn | 69.00 | -- | -- | -- | -- | -3.09 | -3.09 | 0.00 | -0.7607 | 0.00 | -- | -- | 0.00 | -96.69 | -65.05 | -184.49 | -98.10 | -- | -- | -- | -- | -- | -21.71 | 2.33 | -- | -- | -- | -19.29 | -- | -7.33 | -- |
| Qiagen NV | 1.60bn | 326.20m | 8.12bn | 5.65k | 25.73 | 2.94 | 17.11 | 5.06 | 1.68 | 1.68 | 8.26 | 14.70 | 0.3488 | 2.66 | 5.45 | 311,492.70 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 6.65bn | 432.76m | 10.86bn | 65.00k | 25.77 | 2.56 | 10.81 | 1.63 | 2.54 | 2.54 | 38.86 | 25.54 | 0.6671 | 40.83 | 5.17 | -- | 4.32 | 6.78 | 5.48 | 8.46 | 21.40 | 23.08 | 6.48 | 10.10 | 1.03 | 6.34 | 0.492 | 21.89 | 4.96 | 6.05 | -25.14 | -6.70 | 8.60 | 1.15 |
| Genmab A/S | 2.75bn | 1.14bn | 14.93bn | 2.68k | 12.88 | 3.24 | 12.56 | 5.43 | 147.88 | 147.88 | 357.69 | 587.89 | 0.5535 | 16.68 | 3.60 | 8,407,228.00 | 22.89 | 17.70 | 25.72 | 19.07 | 94.27 | -- | 41.35 | 35.77 | 6.01 | -- | 0.0241 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| Lonza Group AG | 6.53bn | 909.00m | 36.59bn | 19.77k | 40.26 | 3.92 | 23.51 | 5.60 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
| argenx SE | 2.77bn | 1.18bn | 39.97bn | 1.60k | 36.38 | -- | -- | 14.44 | 19.48 | 19.48 | 45.96 | -- | -- | -- | -- | 1,899,643.00 | -- | -7.11 | -- | -7.96 | 89.63 | -- | 42.54 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 3.18m | 4.53% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.58m | 3.67% |
| Norges Bank Investment Managementas of 04 Feb 2026 | 2.10m | 2.99% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.31m | 1.86% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 1.20m | 1.71% |
| BlackRock Investment Management (UK) Ltd.as of 13 Feb 2026 | 928.34k | 1.32% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 898.22k | 1.28% |
| Invesco Advisers, Inc.as of 06 Feb 2026 | 825.29k | 1.18% |
| Geode Capital Management LLCas of 12 Feb 2026 | 792.32k | 1.13% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 691.31k | 0.98% |
